Generation of CHO Stable Cell Line Overexpressing HER2: an In Vitro Model for Breast Cancer
Authors
Abstract:
Background: Breast cancer is the most common female malignancy and the leading cause of cancer mortality in women worldwide. The human epidermal growth factor receptor2 (HER2) is a transmembrane tyrosine kinase receptor that is usually overexpressed in human breast cancers. Stable cell lines heterogeneously overexpressing HER2 are highly required as in vitro models for breast cancer research. The aim of this study was to establish a stable cell line overexpressing HER2. Materials and Methods: CHO Cells were transfected with linearized pCVN/HER2 plasmid and selected for the recombinant cells with G418 antibiotic. Expression of HER2 in the transfected cells was analyzed using western blotting and immunofluorescence. Results: We found that the recombinant cells stably expressed high levels of HER2 proteins that were mostly concentrated on the cell membrane. Conclusions: The cell line established here provides a useful in vitro model for breast cancer research and any HER-related studies.
similar resources
Development of a Stable Cell Line, Overexpressing Human T-cell Immunoglobulin Mucin 1
Background: Recent researches have demonstrated that human T-cell immunoglobulin mucin 1 (TIM-1) glycoprotein plays important roles in regulation of autoimmune and allergic diseases, as well as in tumor immunity and response to viral infections. Therefore,targeting TIM-1 could be a potential therapeutic approach against such diseases. Objectives: In this study, we aimed to express TIM-1 protein...
full textan application of equilibrium model for crude oil tanker ships insurance futures in iran
با توجه به تحریم های بین المملی علیه صنعت بیمه ایران امکان استفاده از بازارهای بین المملی بیمه ای برای نفتکش های ایرانی وجود ندارد. از طرفی از آنجایی که یکی از نوآوری های اخیر استفاده از بازارهای مالی به منظور ریسک های فاجعه آمیز می باشد. از اینرو در این پایان نامه سعی شده است با استفاده از این نوآوری ها با طراحی اوراق اختیارات راهی نو جهت بیمه گردن نفت کش های ایرانی ارائه نمود. از آنجایی که بر...
Treatment of HER2-overexpressing breast cancer.
The HER family of receptors consists of four closely related type 1 transmembrane TK receptors: HER1 (EGFR), HER2, HER3 and HER4. Signalling via the HER family of receptors underpins the majority of the intricate array of cellular activities on which cell survival and functionality depend. Aberrant HER2 expression and/or functionality have been implicated in the evolution of breast cancer and t...
full textGeneration of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.
Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in a large percentage of breast cancers. Monoclonal antibodies targeting HER2 are vastly used for both diagnostic and therapeutic aims. However, identifying a new molecular probe against HER2 with improved diagnostic and therapeutic features is of great importance. In this report, we have applied the cell systematic evolut...
full texta novel in vitro model for cancer stem cell culture using ectopically expressed piwil2 stable cell line
objective: piwil2, a member of ago/piwi gene family containing piwi and paz domains, has been shown to be ectopically expressed in different cancer cells, especially its remarkable expression in cancer stem cells (cscs), and is also known to be essential for germ line stem cell self-renewal in various organisms. the hypothesis that csc may hold the key to the central problem of clinical oncolog...
full textMolecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms have been described as cont...
full textMy Resources
Journal title
volume 3 issue 3
pages 6- 10
publication date 2015-08
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023